Cancer incidence and mortality in the Greater Poland Region—Analysis of the year 2010 and future trends

Dyzmann-Sroka, Agnieszka; Malicki, Julian

doi:10.1016/j.rpor.2014.04.001

Cited by 27 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four population cancer registries were able to provide the data as required by the CCORE models: Belgium, the Netherlands, the Greater Poland region of Poland (covering about 10% of Poland [17]) and Slovenia. Data on stage correspond to the years 2010-11 for the Netherlands and Belgium, 2009-10 for Slovenia and 2010 for the Great Poland region.…”

Section: A Two-step Approachmentioning

confidence: 99%

The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project

Borràs

Bartoň

Grau

et al. 2015

Radiotherapy and Oncology

Self Cite

101

View full text Add to dashboard Cite

a b s t r a c tBackground and purpose: The impact of differences in the distribution of major cancer sites and stages at diagnosis among 4 European countries on the optimal utilization proportion (OUP) of patients who should receive external beam radiotherapy was assessed within the framework of the ESTRO-HERO project. Materials and methods: Data from Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) were used. Population based stages at diagnosis from the cancer registries of Belgium, Slovenia, the Greater Poland region of Poland, and The Netherlands were used to assess the OUP for each country. A sensitivity analysis was carried out. Results: The overall OUP by country varied from the lowest of 48.3% in Australia to the highest of 53.4% in Poland; among European countries the variation was limited to 3%. Cancer site specific OUPs showed differences according to the variability in stage at diagnosis across countries. The most important impact on the OUP by country was due to changes in relative frequency of tumours rather than stage at diagnosis. Conclusions: This methodology can be adapted using European data, thus facilitating the planning of resources required to cope with the demand for radiotherapy in Europe, taking into account the national variability in cancer incidence.Ó 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xxx (2015) xxx-xxx Radiotherapy is a key therapeutic approach in the multimodality treatment of cancer. The investment required to set up a radiotherapy facility, the time elapsed from the initial decision until the equipment is fully operational and the need for training highly skilled multi-professional teams are factors that have made the planning of radiotherapy a matter of discussion from a cancer policy making perspective. In order to proceed with such projects, the estimation of demand for radiotherapy is an essential component.Classically, the demand for radiotherapy has been estimated as a percentage of the incident cancer cases with an adjustment for re-treatment rates [1][2][3]. Traditionally the '50%' estimate of incident cases benefitting from radiotherapy was the 'ad hoc' approach. However, this heuristic method has been replaced by three new approaches to the estimation of demand [4-9]:1) an analysis of the utilization of radiotherapy in 'optimal' regions; 2) a criterion-based approach carried out for specific indications, and 3) an evidence-based evaluation of clinical guidelines, including all tumour sites with incidence of more than of 1%.These approaches were reviewed within the framework of the QUARTS project [10]. The third approach was selected as being http://dx

show abstract

Section: A Two-step Approachmentioning

confidence: 99%

The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project

Borràs

Bartoň

Grau

et al. 2015

Radiotherapy and Oncology

Self Cite

101

View full text Add to dashboard Cite

show abstract

“…It constitutes almost 22% of the consideration the ageing of the population, an increase of tumour cases is predicted. 2 Every day 14 Polish women die of breast cancer. Every year the number of deaths exceeds 5000.…”

Section: Background and Aimmentioning

confidence: 99%

What do women know about breast cancer prophylaxis and a healthy style of life?

Sielska

Matecka

Dąbrowska

et al. 2015

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…Thus, it requires better, alternative approaches for improvements in patient life [1,2]. Most of chemotherapeutic agents in use originated from synthetic or natural source but are unable to restrict tumour cell growth [3].…”

Section: Introductionmentioning

confidence: 99%

Leishmanial sphingolipid induces apoptosis in Sarcoma 180 cancer cells through regulation of tumour growth via angiogenic switchover

et al. 2014

View full text Add to dashboard Cite

Sphingolipids are membrane and intracellular lipids that typically modulate cellular processes to cause cell death. Exogenous administration of sphingolipids may cause restriction of tumour growth and several alternative strategies are being used to control the cell growth. The microbes, their cellular component(s) or metabolites like DHA, EPA and also FTY720 have been employed as new therapeutic entities to regulate the disease condition. The therapeutic efficacy of lipids from Leishmania donovani in rheumatoid arthritis and also in sepsis condition associated with inflammatory diseases is well established. In this study, we explored the apoptotic effect of LSPL-1 (leishmanial sphingolipid-1) in Sarcoma 180 cells towards the regulation of tumour growth. The study using a panel of cancer cell lines revealed that LSPL-1 induces cell death in Sarcoma 180. The apoptotic changes were assessed by annexin exposure and DNA content analysis using flow cytometry. LSPL-1 appears to activate several pro- and anti-apoptotic molecules through reactive oxygen species (ROS) generation and also caspase activation, as determined by Western blot and ELISA analyses. Simultaneously, it may improve the survival rate of mice bearing tumour induced by Sarcoma 180 cells, with pathological changes. LSPL-1 may also suppress the cancer-associated inflammatory responses with the expression of matrix metalloproteinase having inhibitory role. It may regulate several angiogenic factors including VEGF, Ang-2 and CD34 in angiogenic events generated in Sarcoma 180 cell-induced tumour. These studies underline the significance of anti-neoplastic potential of LSPL-1 through apoptosis induction and abrogation of angiogenic responses in Sarcoma 180 cell-associated tumour.

show abstract

Cancer incidence and mortality in the Greater Poland Region—Analysis of the year 2010 and future trends

Cited by 27 publications

References 15 publications

The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project

The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project

What do women know about breast cancer prophylaxis and a healthy style of life?

Leishmanial sphingolipid induces apoptosis in Sarcoma 180 cancer cells through regulation of tumour growth via angiogenic switchover

Contact Info

Product

Resources

About